PANZYGA showed proven results in a clinical trial
In the clinical trial, 51 adult and pediatric patients with primary immunodeficiency received PANZYGA for one year (360 days) to see how well patients responded to treatment with PANZYGA.
PANZYGA helped reduce serious bacterial infections
*Serious bacterial infections included pneumonia, bacteremia or sepsis, osteomyelitis/septic arthritis, visceral abscesses, or bacterial meningitis.
†Person-years take into account both the number of patients in the trial and the amount of time each patient spends in the trial.
Additional findings in the 1-year trial showed:
Low rate of hospitalizations
The rate of hospitalizations due to infection was 0.1 days per person-year. This means that 1 patient was hospitalized for 4 days
Low amount of antibiotic use
There were 3.0 treatment episodes with antibiotics per person-year
Low rate of other infections
There were 3.7 infections per person-year. These were not serious bacterial infections
Low rate of absences
There were 3.6 days missed of work or school per person-year due to infections
Why does infusion speed matter?
PANZYGA is the only FDA-approved IVIg for PI with the fastest approved maximum infusion rate.‡
This could mean less time spent on your infusion.
Here are 2 examples of infusion times and infusion rates with PANZYGA at different doses§:
‡Maximum infusion rate=14 mg/kg/min, as tolerated.
§The specific times will depend on how well the person tolerates the infusion.
Most common side effects
In the clinical trial, more than 5% of patients experienced these side effects:
Headache: 22%
Stomach pain (upper): 14%
Fever: 14%
Nausea: 10%
Sinus infection: 8%
Fatigue: 6%
Bronchitis: 6%
